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The capacity to assess environmental inputs to biological phenotypes is limited by methods
that can accurately and quantitatively measure these contributions. One such example can be
seen in the context of exposure to ionizing radiation.
Methods and Findings
We have made use of gene expression analysis of peripheral blood (PB) mononuclear cells to
develop expression profiles that accurately reflect prior radiation exposure. We demonstrate
that expression profiles can be developed that not only predict radiation exposure in mice but
also distinguish the level of radiation exposure, ranging from 50 cGy to 1,000 cGy. Likewise, a
molecular signature of radiation response developed solely from irradiated human patient
samples can predict and distinguish irradiated human PB samples from nonirradiated samples
with an accuracy of 90%, sensitivity of 85%, and specificity of 94%. We further demonstrate that
a radiation profile developed in the mouse can correctly distinguish PB samples from irradiated
and nonirradiated human patients with an accuracy of 77%, sensitivity of 82%, and specificity of
75%. Taken together, these data demonstrate that molecular profiles can be generated that are
highly predictive of different levels of radiation exposure in mice and humans.
Conclusions
We suggest that this approach, with additional refinement, could provide a method to assess
the effects of various environmental inputs into biological phenotypes as well as providing a
more practical application of a rapid molecular screening test for the diagnosis of radiation
exposure.
The Editors’ Summary of this article follows the references.
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Environmental risks and individual genetic repertoires are
considered to be the primary inﬂuences that dictate a
person’s susceptibility to disease. However, for any given
disease, accurate estimation of the contribution of either
environmental inﬂuences or genotype to disease develop-
ment can be difﬁcult. Once an association between a given
environmental exposure and a particular biological pheno-
type has been suggested, it is important, if possible, to
prospectively determine whether the environmental expo-
sure has a causative or predictive impact on the biological
phenotype.
Ionizing radiation is an example of a ubiquitous and
potentially dangerous environmental hazard that has been
associated with the development of thyroid cancers, multiple
myeloma, and myeloid leukemias in children and adults [1–3].
Following the atomic bombings at Hiroshima and Nagasaki,
many studies were performed to assess the incidence of
speciﬁc genetic mutations, such as p53 and HPRT mutations,
in somatic cells from survivors of these events [4–6].
Furthermore, Neel et al. performed comprehensive mortality
and phenotype studies of children of atomic bomb survivors,
which surprisingly have not revealed an overt increase in
mutagenesis or teratogenesis in F1 offspring [7–9]. However, a
comprehensive characterization of the genetic changes that
can occur in human populations exposed to ionizing
radiation (e.g., Chernobyl reactor accident victims) has not
been performed, and quantiﬁcation, at the genetic level, of
the impact of radiation exposure on the risk of developing
such diseases has not been measured.
Recently, the potential hazard of ionizing radiation
exposure has been identiﬁed as both a public health and
national security risk [10–13] in light of the anticipated use of
radiological or nuclear materials by terrorists to make ‘‘dirty
bombs’’ or ‘‘improvised nuclear devices’’ [10–13]. In addition,
preliminary studies have now been performed utilizing gene
expression analysis of tumor cells and cell lines [14,15],
primary cells [16], rodents [17], and peripheral blood (PB)
from small numbers of patients [18] to identify genes whose
expression is altered following exposure to radiation. In the
event of a dirty bomb or a higher-impact nuclear detonation,
thousands of individuals may present for immediate medical
attention to determine whether they have been exposed. It
would be critical in such an event for caregivers to have the
capability to rapidly triage which individuals have received
deterministic exposures versus the ‘‘worried well’’; biological
dosimetry becomes even more critical when considered in
light of the limitations of the current tools available to
estimate an individual’s exposure level. Lymphocyte deple-
tion kinetics require several (.3–7) daily complete blood
counts to provide accurate prediction of dose received, and
decline can lag for 48 hours even in heavily exposed
individuals [12,13]. Cytogenetics analyses are the current gold
standard to measure the dicentric DNA breaks that occur
following radiation exposure [12,13,19] but require several
days to complete.
One approach to achieve a faster and potentially highly
sensitive measurement of radiation exposure would be the
utilization of high-throughput gene expression analyses to
identify patterns of molecular changes that occur following
exposure. Such an approach, targeting a radiosensitive and
easily accessible cell population, such as PB lymphocytes
[20], could potentially lead to a validated panel of ‘‘radiation
response’’ genes that have yet to be identiﬁed and could be
translated into a rapidly applicable diagnostic screening test.
Our group has utilized genomic analyses to identify genes
predictive of prognosis within several types of cancers [21–24]
as well as genes that predict patient response to chemo-
therapy [21]. Gene expression analysis of PB leukocytes has
also been applied to distinguish patients with atherosclerosis
from individuals without it [25] and to identify variations in
gene expression among healthy individuals [26]. We sought to
determine whether a similar strategy could be applied to
determine which genes will predict different levels of
radiation exposure and possibly allow stratiﬁcation of
individuals on the basis of their genomic proﬁles. We have
demonstrated that genome-scale measures of gene expres-
sion, together with advanced computational tools, can
successfully generate molecular signatures that distinguish
clinically relevant levels of radiation exposure in mice and
humans.
Methods
C57B16 Murine Irradiation Studies
We housed ten-week-old C57Bl6 female mice (Jackson
Laboratory, http://www.jax.org) at the Duke Cancer Center
Isolation Facility and studied them under speciﬁcations
approved by the Duke University Animal Care and Use
Committee. Mice (n ¼ 7–10 per group) were irradiated with
either 50 cGy total body irradiation (TBI), 200 cGy, or 1,000
cGy delivered by a Cs137 irradiator at a dose rate of 480 cGy/
min. PB (500 ll) was collected via ocular bleed from each
irradiated mouse 6 h following exposure of the mice to TBI,
and an equal amount was collected from nonirradiated
control mice. PB mononuclear cells (MNCs) were collected via
Ficoll-Hypaque centrifugation, and total RNA was isolated
from these cells as we have previously described [27]. Total
RNA quality was assessed by an Agilent Bioanalyzer 2100
(Agilent Technologies, http://www.agilent.com).
Human Irradiation Studies
Patients undergoing TBI as part of their pretransplanta-
tion conditioning and healthy donors were enrolled to
participate in this study following a protocol to collect PB
samples that was previously approved by the Duke University
Institutional Review Board. All patients receiving non-
myeloablative conditioning were treated with 200 cGy of
TBI from a linear accelerator at a dose rate of 20 cGy/min.
All patients who underwent TBI-based myeloablative alloge-
neic or autologous stem-cell transplantation received radi-
ation fractionated at 150 cGy per fraction at 20 cGy/min. All
patients had PB collected (50 ml) prior to and 6 h following
exposure to either 200 cGy or 150 cGy radiation treatment.
Certain patients also received 30 mg/m
2 of ﬂudarabine
intravenously on days  5 through  2 and 500 mg/m
2 of
cyclophosphamide intravenously on days  5 through  2a s
further immunosuppressive therapy. The irradiation was
administered one day prior to the initiation of the
ﬂudarabine and cyclophosphamide, and the PB samples
were drawn prior to the exposure to these immunosuppres-
sive agents. MNCs were collected from each patient’s PB
using the identical Ficoll Hypaque methodology described
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isolated.
DNA Microarrays
Mouse and human oligonucletotide arrays were printed at
the Duke Microarray Facility using Operon’s Mouse Genome
Oligo set (version 3.0) (https://www.operon.com), which
contains 31,769 70-mer probes representing 24,878 genes
and 32,829 transcripts, and the Operon Human Genome
Oligo set version 3.0, which possesses 34,580 optimized 70-
mers, representing 24,650 genes.
RNA and Microarray Probe Preparation and Hybridization
Brieﬂy, 5 3 10
6 MNCs were pelleted, and total RNA was
isolated using the RNAeasy minispin column [27]. Total RNA
(2 lg) from each sample (mouse or human) and the universal
reference RNA (Universal Human or Mouse Reference RNA,
Stratagene, http://www.stratagene.com) were used in probe
preparation. The reference RNA allows for the signal for
each gene to be normalized to its own unique factor allowing
comparisons of gene expression across multiple samples. This
serves as a normalization control for two-colored micro-
arrays and an internal standardization for the arrays. The
relative ranges of gene expression for each analysis were
measured by using the median of ratios (sample/Stratagene
universal reference). Brieﬂy, reverse transcription was driven
by an oligo (dT) primer bearing a T7 promoter using
ArrayScript. The cDNA then underwent second-strand syn-
thesis and clean-up to become a template for in vitro
transcription with T7 RNA polymerase. To maximize RNA
yield, Ambion’s (http://www.ambion.com) proprietary MEGA-
script in vitro transcription (IVT) technology was used to
generate ampliﬁed RNA (aRNA). The antisense aRNA was
then ﬂuorescently labeled with Cy3 (reference) and Cy5
(sample). Sample and reference aRNAs were pooled, mixed
with 13 hybridization buffer (50% formamide, 53 SSC, and
0.1% SDS), COT-1 DNA, and poly-dA to limit nonspeciﬁc
binding, and heated to 95 8C for 2 min. This mixture was
pipetted onto a microarray slide, a cover slip was placed, and
it was hybridized overnight at 42 8C. The array was then
washed at increasing stringencies, and scanned on a GenePix
4000B microarray scanner (Axon Instruments, http://www.
axon.com). Detailed protocols are available on the Duke
Microarray Facility Web site (http://microarray.genome.duke.
edu/). The expression levels of representative genes from the
gene array analysis were conﬁrmed via real-time quantitative
RT-PCR analysis. The High Capacity cDNA Archive kit
(Applied Biosystems, http://www.appliedbiosystems.com) was
used to generate cDNA from total RNA from each sample.
Each sample was assayed in duplicate using 5-ng cDNA
(TaqMan Mastermix and TaqMan Gene Expression Assays
real-time PCR primers ([Applied Biosystems]) and analyzed
on an ABI Prism 7900HT Sequence Detection system
(Applied Biosystems) according to the manufacturer’s pro-
tocol.
Data Processing and Statistical Analysis
Genespring 6.1 (Agilent Technologies) was used to perform
initial data ﬁltering in which spots whose signal intensities
below 100 in either the Cy3 or Cy5 channel were removed. To
then account for missing values, PAM software (http://
www-stat.stanford.edu/;tibs/PAM/) was used to impute miss-
ing values. k-nearest neighbor was used where missing values
are imputed using a k-nearest neighbor average in gene
space. For the hierarchical clustering analysis only those
genes that varied across all conditions (2,213 probes) were
applied through GeneCluster 3.0 [28]. Genes and samples
were clustered using average linkage with centered correla-
tion similarity metric, and the results were visualized in
JavaTreeview [29]. Gene expression data in the mouse and
human predictive analyses were ﬁltered to exclude probe sets
that had signal intensities below background signal level as
well as genes that did not vary signiﬁcantly across samples
(6,793 mouse probes and 11,319 human probes). The
expression signature for each dose response represents a
group of genes as a single expression proﬁle and is here
derived as the top principal component, or metagene.
Prediction analysis of the expression data was performed
using MATLAB software as previously described for the
analysis of breast cancer samples [22]. When predicting levels
of radiation exposure, gene selection and identiﬁcation is
based on training the data and ﬁnding those genes most
highly correlated to response. Each signature summarizes its
constituent genes as a single expression proﬁle and is here
derived as the ﬁrst principal component of that set of genes
(the factor corresponding to the largest singular value), as
determined by a singular value decomposition. Given a
training set of expression vectors (of values across metagenes)
representing two biological states (nonirradiated and irradi-
ated), a binary probit regression model is estimated using
Bayesian methods. Bayesian ﬁtting of binary probit regres-
sion models to the training data then permits an assessment
of the relevance of the metagene signatures in within-sample
classiﬁcation, and estimation and uncertainty assessments for
the binary regression weights mapping metagenes to prob-
abilities of radiation exposure. To internally validate the
predictive capacity of the metagene proﬁles, we performed
leave-one-out cross validation studies as we have previously
described [22]. To externally validate the mouse-metagene
proﬁles, we validated against prospectively collected, blinded
human PB samples. To map the probe sets across species
(mouse to human) we used an in-house program Chip
Comparer (http://tenero.duhs.duke.edu/genearray/perl/chip/
chipcomparer.pl). Each Operon probeset ID was mapped to
a corresponding LocusID. This mapping was done by parsing
local copies of LocusLink and UniGene databases to identify
the inherent relationship between the GenBank accession
number associated with each probeset sequence and its
corresponding LocusID. Probesets from different arrays are
matched by sharing the same orthologous pair of LocusIDs
(across species). A total of 7,101 probes was mapped between
the mouse and human operon probe sets and was used in
validating the mouse model in the human samples. These
patterns were then applied against the human samples in a
blinded manner to determine the predictive capacity of each
metagene proﬁle against human PB samples from non-
irradiated and irradiated patients. Genes found to be
predictive of radiation dose were characterized utilizing an
in-house program, GATHER (http://meddb01.duhs.duke.edu/
gather/). GATHER quantiﬁes the evidence supporting the
association between a gene group and an annotation using a
Bayes factor [30]. All raw data ﬁles are found at http://data.
cgt.duke.edu/Chute.php.
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Development of a Radiation-Response Gene Expression
Signature
As a strategy to develop gene expression proﬁles that could
predict different levels of radiation exposure, ten-week-old
C57Bl6 mice (n¼7 per group) were exposed to either 50 cGy,
200 cGy, or 1,000 cGy TBI as a single fraction from a Cs137
gamma source at a dose rate of 480 cGy/min (Figure 1). We
chose these doses of irradiation since each represents an
exposure with different expected medical implications. For
example, 50 cGy exposure is low level and causes no acute
medical deﬁcits; 200 cGy is both immunosuppressive and
myelosuppressive and could cause important clinical sequelae
(e.g., infections) requiring medical intervention (i.e., anti-
biotics and growth factor administration); 1,000 cGy would
likely be a lethal exposure despite maximal supportive care
(i.e., transfusion support and antibiotics). We compared mice
irradiated at these doses with nonirradiated control mice (0
cGy). PB samples (500 ll) were collected from each mouse 6 h
following irradiation, PB MNCs were isolated via Ficoll
Hypaque centrifugation, and total RNA was extracted from
the PB MNCs from each mouse in the experimental groups
along with seven nonirradiated controls. Microarray analyses
were performed as described in the Methods. We identiﬁed
genes whose expression most highly correlated with exposure
to radiation at a particular dose. Using a ﬁltered gene list of
2,213 transcripts, we ﬁrst performed an unsupervised analysis
of the gene expression data from all samples to determine if
there was structure evident in the expression information
that reﬂected radiation exposure. Indeed, as shown in Figure
2A, an analysis of the data by hierarchical clustering revealed
clear patterns of gene expression that separated the non-
irradiated samples from the irradiated samples. Moreover, it
was also evident that the clusters separated the samples as a
function of radiation dose. These conditions of radiation
exposure resulted in distinct gene expression events.
Given the evident patterns of gene expression reﬂecting
exposure to radiation, we then used a supervised binary
regression analysis to speciﬁcally focus on those patterns of
gene expression, or what we term metagenes, that best
classiﬁed and predicted the event of radiation exposure.
Based upon a ﬁltered gene list of 6,793 probes, a pattern of
gene expression could be identiﬁed that effectively distin-
guished the control animals from those that were irradiated
(Figure 2B). A critical aspect of these analyses is the ability to
validate the classiﬁcations, testing that a pattern reﬂecting
the radiation response does indeed have the capacity to
actually predict the status of an unknown sample as opposed
to being merely a chance association. To verify that these
patterns did indeed represent genes reﬂecting the exposure
to radiation, we utilized a leave-one-out cross-validation to
assess the ability of the pattern to predict the relevant
samples (Figure 2B, right). The results demonstrate that the
pattern selected for distinguishing control animals from
those irradiated at various doses does indeed have the
capacity to predict the status of these samples. We conclude
from these results that it is possible to identify a gene
expression signature that reﬂects a response to radiation.
Radiation Dose-Specific Gene Expression Signatures
Given the ability to develop a signature reﬂecting radiation
response, we proceeded to determine if expression signatures
could be identiﬁed that were speciﬁc to the actual level of
radiation. As shown in Figure 3A–3C (left), a series of proﬁles
was identiﬁed that distinguished the control samples from
samples irradiated at increasing doses. And again, each of
these proﬁles was then validated via leave-one-out cross
validation analysis, demonstrating the capacity to accurately
predict the status of a sample treated as an unknown (Figure
3A–3C, right). This is most clear when distinguishing controls
from 200 cGy or 1,000 cGy exposures (Figure 3B and 3C),
possibly reﬂecting more pronounced effects on transcription
at these higher dose exposures. Nevertheless, the results are
quite clear that there are patterns that can be discerned with
an ability to predict exposure to radiation.
The proﬁles that can distinguish between a control animal
and one exposed to various doses of radiation are based on a
collection of 75–100 genes per proﬁle. A complete list of
these discriminatory genes (annotated genes and ESTs) is
provided in Table S1. The gene ontology categories repre-
sented by the genes selected for distinguishing various levels
of radiation exposure are summarized in Table S2. The most
signiﬁcant annotations are shown in order of decreasing
signiﬁcance. Of note, while 21 annotated genes were overex-
pressed in common between the 200 cGy and 1,000 cGy
exposure levels, only two annotated genes, etoposide-induced 2.4
mRNA (Ei24), protein-phosphatase 1 regulatory inhibitor subunit 2
(Ppp1r2), and three nonannotated genes, M300006426,
Figure 1. Scheme for Development of Radiation Response Expression
Signature
PB MNCs were collected from control (0 cGy), 50 cGy-irradiated, 200 cGy-
irradiated, and 1,000 cGy-irradiated C57Bl6 mice. Gene array analyses
were performed on RNA isolated from n ¼ 7 replicates from each
condition, and metagene profiles were developed to represent the four
different levels of radiation exposure. A leave-one-out cross-validation
study was performed, which revealed the highly predictive nature of
these metagene profiles. Finally, these profiles were independently
validated by blinded analysis of PB samples from human patients who
had undergone TBI to determine the capacity for these profiles to predict
human radiation exposure.
doi:10.1371/journal.pmed.0040106.g001
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Metagene of Radiation ResponseFigure 2. Gene Expression Profiles that Reflect Radiation Exposure
(A) Clustering of samples based on gene expression patterns reflects radiation exposure. Hierarchical cluster analysis of a filtered list of 2,213 probe sets
from expression data of PB MNCs from mice irradiated at varying dosages is shown (a, normal; b, 50 cGy; c, 200 cGy; d, 1,000 cGy). Each gene is
represented by a single row, and each sample is represented by a single column. The color red represents expression ratios of overexpressed genes,
green represents expression ratios of underexpressed genes, and black represents expression ratio of 0 (similar expression in both samples). The relative
expression ranges from 0.02 to 610.
(B) A supervised analysis to identify an expression profile that distinguishes control samples from irradiated samples is shown. On the left, PB MNCs
were prepared from either control mice or mice irradiated at the indicated dose. RNA was extracted and used for the synthesis of probes for microarray
analysis. The left images depict the expression pattern of genes selected for classifying irradiated samples from control. The expression of genes is
standardized to zero mean and unit variance across samples, which are displayed with each row as a gene ordered vertically by the estimated
regression weights. Each column is a sample from an independent experiment. High expression is depicted as red, and low expression is depicted as
blue, and the range of expression is from 0.02 to 610. The images on the right depict leave-one-out cross validation of the classification probabilities at
each dose. Each sample, including the controls and the irradiated samples, is predicted as a probability of exhibiting a gene expression signature
reflecting the irradiated sample’s specific pattern along with 95% confidence intervals indicated as dashed vertical lines. Each sample is plotted as its
predicted probability of radiation response (red) versus nonresponse (blue) on the basis of the analysis of the remaining samples. Each sample is
represented as a number in the chronological order of the dose of radiation received; e.g., samples 1–7 are from nonirradiated controls, 8–14 are from
50-cGy irradiated animals, 15–21 are from 200-cGy irradiated animals, and 22–28 are from 100-cGy irradiated animals.
doi:10.1371/journal.pmed.0040106.g002
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Metagene of Radiation ResponseM300017997, M300015969, were found to be in common
across the three different proﬁles (Figure S1). Quantitative
real-time PCR analysis conﬁrmed the integrity of the gene
expression levels obtained in the gene arrays (Figure S1).
Moreover, a dose-response effect was not evident in the
majority of genes within the metagene proﬁles; for example,
of the 100 genes within the proﬁle of 50-cGy exposure, only
12 (12%) demonstrated a further increase in expression at
200 cGy and 1,000 cGy. Taken together, these data suggest
that each different level of radiation exposure induced a
unique hierarchy of transcriptional events, rather than an
escalating biological response from a select group of genes.
The overexpression of Ei24 in all three proﬁles suggests the
integrity of these predictors, since this is a pro-apoptotic
factor that would be expected to be up-regulated in response
to ionizing radiation exposure [31]. Taken together, these
Figure 3. Gene Expression Profiles that Predict Dose of Radiation Exposure
The left images depict the expression pattern of genes selected for classifying control, nonirradiated samples versus 50-cGy (A), 200-Gy (B), or 1,000-cGy
(C) exposure. The right graphs depict a leave-one-out cross validation of the classification probabilities of control versus 50 cGy (A), control versus 200
cGy (B), or control versus 1,000 cGy (C). High expression is depicted as red, and low expression is depicted as blue; the relative expression levels for 0
versus 50 cGy range from 0.29 to 10.5, 0 versus 200 cGy range from 0.26 to 26.3, and 0 versus 1,000 cGy range from 0.17 to 48.77. Each sample is
represented as a number in the chronological order of the dosed sample.
doi:10.1371/journal.pmed.0040106.g003
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associated with radiation and that distinct biological pro-
cesses are activated as a function of radiation dose.
The fact that the gene expression proﬁles selected for
predicting each dose of radiation were largely nonoverlap-
ping suggested that these were distinct proﬁles and thus
suggested the potential for developing predictors that could
not only distinguish radiation from control but that could
also distinguish the dose of radiation. To address this
possibility, we redeveloped the predictors of radiation
response by focusing on the development of proﬁles that
would distinguish a particular dose of radiation from not only
control samples but also from each of the other irradiated
samples. As shown in Figure 4 (left), expression proﬁles were
identiﬁed that distinguished 50 cGy, 200 cGy, and 1,000 cGy
samples not only from control samples but also from each of
the other irradiated samples. A leave-one-out cross-validation
analysis conﬁrmed the effectiveness of these proﬁles toward
distinguishing one level of radiation exposure versus the
other levels (Figure 4, right). In each case, the proﬁles
developed for a particular radiation dose proved to be highly
accurate in predicting the relevant samples, with only one
incorrectly categorized sample from n ¼ 28 analyzed in each
experiment.
A Radiation Response Signature Can Predict Radiation
Exposure in Human Samples
As a complementary approach, we sought to develop a
metagene proﬁle of human radiation exposure solely using
PB samples collected from healthy donors and stem cell
transplant patients prior to and six hours following TBI with
150 cGy or 200 cGy. For these studies, 22 patients were
enrolled who received 200 cGy as a single fraction prior to a
nonmyeloablative transplant. A total of nine patients were
enrolled who received myeloablative fractionated irradiation
(1,350 cGy) prior to allogeneic stem cell transplant, and ﬁve
patients were enrolled who received myeloablative fractio-
nated TBI (1,200 cGy) prior to autologous transplant. PB
samples were also collected from three patients prior to
receiving nonradiation-based conditioning as well as 18
healthy donors. The clinical characteristics of the enrolled
patients are summarized in Table S3. Sufﬁcient RNA was
isolated from all 18 healthy human donors, 33 patients prior
to receiving TBI or high dose chemotherapy conditioning,
and 27 irradiated patients. For the gene expression analysis, a
ﬁltered human gene list of 11,319 probes was utilized. A
supervised binary regression analysis identiﬁed a metagene
proﬁle of 25 genes (Figure 5A), which effectively distin-
guished the nonirradiated human samples from those from
irradiated patients. A leave-one-out cross-validation analysis
conﬁrmed that this proﬁle correctly predicted the human
samples with an overall accuracy of 90%, a sensitivity of 85%,
and a speciﬁcity of 94% (Figure 5A). Analysis of the 20
patients from whom both pre- and postirradiation samples
were available demonstrated that the human metagene
proﬁle accurately predicted 18 of 20 (90%) preirradiation
samples and 17 of 20 (85%) postirradiation samples. A Mann-
Whitney log rank test was performed, which demonstrated a
highly signiﬁcant difference between the predicted proba-
bilities of the healthy donors, nonirradiated patients, and the
irradiated patients (p , 0.0001). The list of genes contained
within the human predictor is provided in Table S4. The gene
ontology categories represented by the human genes selected
for distinguishing various levels of radiation exposure are
summarized in Table S5.
To extend this analysis further, we asked if the predictive
signature developed in the mouse could cross over to predict
radiation exposure in humans. The potential advantage of
this approach is the utility of the mouse in developing dose-
speciﬁc signatures, something not easily achievable with
human participants. For these studies, the same patient
samples analyzed in Figure 5A were employed as a validation
set for the mouse predictors. A total of 7,101 probes were
mapped between the mouse and human operon probe sets
and were used in validating the mouse model in the human
samples. Of the three mouse predictors, the human homolog
of 1,000 cGy (271 genes) showed the highest accuracy of
prediction of the human samples. This predictor identiﬁed
the human samples with an overall accuracy of 77%,
sensitivity of 82%, and speciﬁcity of 75% (Figure 5B).
Interestingly, the mouse predictor was 100% accurate (18/
18) in identifying the samples from healthy donors as
nonirradiated, but less accurate in distinguishing samples
from pre-stem-cell transplant patients as nonirradiated (20/
33, 61%). A Mann-Whitney log rank analysis demonstrated a
highly signiﬁcant difference between the predicted proba-
bilities of the samples from healthy donors, nonirradiated
patient samples, and the samples from irradiated patients (p
, 0.0001). Taken together, these results indicate that this
metagene proﬁle of radiation response developed in the
mouse performed exceptionally well in identifying healthy
individuals as nonirradiated but less well in individuals with
complex and advanced malignancies who had received
extensive prior chemotherapy and radiotherapy. However,
when this heterogeneous patient population underwent acute
(therapeutic) radiation exposure, the accuracy of the meta-
gene proﬁle increased, demonstrating the sensitivity of the
proﬁle to detect 150- or 200-cGy exposure even within a
markedly heterogeneous human population. Of note, only
one gene, protein kinase C-eta (PRKCH), an anti-apoptotic
factor [32], was found to be in common between the human
derived predictor (25 genes) and the human homolog of the
mouse 1,000 cGy predictor (271 genes). These data suggest
that certain aspects of the molecular response to radiation
may be very different in rodents compared to humans.
Discussion
The ability to assess exposure to ionizing radiation, both to
measure adverse effects that might result from low level
exposure and to assess the extent of exposure following
exposure to high-level radiation, could have a signiﬁcant
impact on subsequent clinical care. With this in mind, we
have sought to develop gene expression signatures that could
reﬂect radiation exposure and have the capacity to discrim-
inate based on the exposure level. More broadly, these studies
have the potential to identify speciﬁc genes and pathways
involved in radiation-induced cellular damage and, therefore,
targets for radioprotective intervention. An examination of
the functional categories represented within the mouse
radiation proﬁles revealed protein and cellular biosynthesis
and immune response as highly represented gene predictor
functions (Table S2). Additionally, individual genes involved
in DNA repair (e.g., recombination activating gene 1 [Rag1]) [33]
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To internally validate the metagene profiles, the predictive capacity of each profile was analyzed with regard to distinguishing nonirradiated samples
from each of the irradiated samples. The heatmaps in the left depict the expression profiles of genes selected to discriminate the dose of radiation; high
expression is depicted as red, and low expression is depicted as blue; the ranges of relative expression levels are the same as in Figure 3: 0 versus 50 cGy
range from 0.29 to 10.5, 0 versus 200 cGy range from 0.26 to 26.3, and 0 versus 1,000 cGy range from 0.17 to 48.77. The right graphs depict a leave-one-
out cross validation analysis to demonstrate that in each case, the profiles developed for a particular radiation dose predicted the relevant samples with
a high level of accuracy. The samples from normal (nonirradiated) mice are represented as blue, samples from 50-cGy irradiated are red, samples from
200-cGy irradiated are green, and samples from 1,000-cGy irradiated mice are orange. As shown, the predictors for 50-cGy, 200-cGy, and 1,000-cGy
irradiation misclassified only one sample out of 28 analyzed in each case, indicating a high level of accuracy of prediction.
doi:10.1371/journal.pmed.0040106.g004
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domains, subfamily A, member 1 [Ms4a1]) [34] were identiﬁed.
More generally, biological processes including apoptosis (e.g.,
Ei24) were highlighted. While it may be premature to
consider how the biological processes represented by the
radiation response genes we have identiﬁed may be exploited
for therapeutic purposes, these results clearly provide clues
to guide future studies focused on this goal.
A more practical application of these methods can be seen
in the context of heightened concerns regarding the risk of
terrorist-mediated attacks using radiological or nuclear
weapons. These articulated concerns have prompted renewed
focus on the development of countermeasures to the effects
of ionizing radiation injury [10–13]. Experimental models
have demonstrated that many interventions aimed at
ameliorating the effects of radiation depend on the early
administration of such therapies (e.g., cytokine administra-
tion for marrow protection), after which their effectiveness
wanes [20,35,36]. In the event of a ‘‘dirty bomb’’ or detonation
of an ‘‘improvised nuclear device,’’ it is clear that thousands
to tens of thousands of individuals, many of whom will
represent the ‘‘worried well,’’ will present for medical
evaluation [10–13] as occurred following the accidental
Cs137 exposure in Goiania, Brazil [37]. Since the symptoms
of ionizing radiation exposure can be mild to absent within
the ﬁrst days to weeks, it would be difﬁcult for health care
professionals to distinguish those truly exposed from the
‘‘worried well’’ without a rapid and sensitive test to make this
distinction. In this study, we show that patterns of gene
expression changes (metagenes) in the PB can be identiﬁed
that distinguish medically relevant levels of radiation
exposure. For example, the metagene proﬁle we developed
for 0-cGy exposure (nonexposed) demonstrated 100% accu-
racy in distinguishing nonexposed mice from those exposed
to as little as 50 cGy. This approach therefore has the
potential to facilitate the correct identiﬁcation of the
‘‘worried well’’ from those even with relatively low-level
radiation exposure, which would be a critical ﬁrst step in any
mass casualty event. Not surprisingly, the metagene proﬁles
we developed to predict higher levels of radiation exposure
(200 cGy and 1,000 cGy) provided more obvious distinction
Figure 5. Metagene Profiles Generated in Mice and Humans Can Predict Radiation Exposure
(A) A metagene profile of human radiation exposure generated in humans is represented. The heatmap on the left depicts the expression profiles of
genes (rows) selected to discriminate the human samples (columns); high expression is depicted as red, and low expression is depicted as blue with the
relative expression level ranging from 0.06–139.0. Healthy, healthy donors; Non-Irradiated Pts, nonirradiated patients; Irradiated Pts, irradiated patients.
In the right image samples from irradiated patients are shown in red, whereas the samples from nonirradiated patients (gray) and healthy donors (black)
are shown. The human metagene profile correctly distinguished 90% (85% sensitivity and 94% specificity) of the irradiated human samples versus the
nonirradiated human samples.
(B) A metagene profile of human radiation exposure generated in mice is represented. Samples from irradiated patients are shown in red, whereas the
samples from nonirradiated patients (gray) and healthy donors (black) are shown. In an external validation study, the metagene profile of 1,000 cGy
from the mouse successfully identified 77% (82% sensitivity and 75% specificity) of the irradiated human samples versus the nonirradiated human
samples.
doi:10.1371/journal.pmed.0040106.g005
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Metagene of Radiation Responsethan the 50-cGy proﬁle with regard to distinguishing any level
of irradiation versus nonirradiated samples.
The approach we have taken to utilize gene expression
proﬁles to predict radiation exposure has been further
validated by our human studies in which a metagene proﬁle
generated solely from human samples demonstrated an
accuracy of 90% in distinguishing healthy donors, non-
irradiated patients, and irradiated patients. Given the
heterogeneous nature of the human population we have
studied, this level of accuracy of the human predictor in
distinguishing irradiated and nonirradiated patients was
encouraging. The fact that a highly accurate predictor could
be generated from the human samples also demonstrates the
potential for identifying relevant information in human PB
samples. We plan to externally validate this predictor against
a larger cohort of irradiated patients and anticipate that
further analysis and reﬁnement of these human signatures
could generate a predictor of radiation response with
substantial accuracy. Comparison of this human metagene
proﬁle of radiation response with a set of human radiation-
induced biomarkers described by Amundson et al. [18]
revealed only one transcript, DNA-damage binding-protein
2, which was overexpressed in both studies. The lack of
overlap between these two studies may reﬂect differences in
gene representation on the different arrays utilized (Human
Operon array representing 24,650 genes versus a 6,485-
element cDNA array) or the different number of patient
samples that underwent array in each study (60 patients
versus one patient) [18].
As further proof-of-principle of the potential application
of these predictive tools to human patients, we sought to
prospectively test the metagene proﬁles of radiation response
developed in mice against PB samples collected from both
healthy volunteers and stem cell transplantation patients
prior to and six hours following TBI with 150 cGy or 200 cGy.
The mouse predictor of 1,000 cGy demonstrated an overall
accuracy of 77% in predicting the human PB samples
correctly. Given that this is the ﬁrst study, to our knowledge,
to attempt to apply a metagene proﬁle to predict radiation
response in humans and the heterogeneous nature of the
patients being studied, we believe this level of accuracy is
encouraging. Moreover, the 100% accuracy of the mouse
predictor in identifying 18 healthy donors as ‘‘nonirradiated’’
suggests the potential utility of this approach in screening
healthy members of a given community for radiation
exposure. Conversely, the lower level of accuracy of the
mouse predictor in identifying nonirradiated transplant
patients as ‘‘nonirradiated’’ (61%) indicates that further
reﬁnement of this signature will be necessary and that such
an approach may have difﬁculty when testing individuals with
complex diseases or those undergoing medical therapies.
Since a variety of hematological diseases were represented in
this patient cohort, and 37 of the 39 patients (95%) had
received some form of cytotoxic chemotherapy prior to
enrollment, we were unable, in this study, to measure the
impact of these two variables on gene expression in these
patients. We anticipate that enrollment of additional patients
over time will allow the impact of these factors to be more
formally measured.
The relative radioresistance of rodents compared to
humans also may have impacted the accuracy of the mouse-
metagene proﬁles when applied against human samples [38–
41]. For example, several studies have demonstrated that
primary human cells in culture are 2- to 4-fold more sensitive
to the deleterious effects of ionizing radiation as compared to
rodent cells in culture [38–41]. In this study, the 200-cGy
mouse-metagene proﬁle successfully distinguished only 62%
of the 200-cGy irradiated human samples, whereas the mouse
1,000-cGy metagene proﬁle demonstrated substantially better
accuracy (77%). Examination of additional doses of radiation
in mice over time will provide the potential for further
reﬁnement of the mouse predictor as applied against human
samples. Moreover, since the mouse-metagene proﬁles
described here were generated from female, adult mice from
a single strain, we recognize that additional studies of both
genders, young and old mice, multiple strains, and the impact
of time on the stability of the metagene proﬁles will be
important for further reﬁnement of this approach. Nonethe-
less, the fact that a mouse proﬁle could predict human
radiation exposure suggests that further reﬁnement of the
mouse signature, to include proﬁles derived from higher
doses, could be effective in generating a dose-speciﬁc
predictor of human radiation exposure.
Finally, we return to what we believe represents a more
general implication of this work. Although prediction of
radiation exposure can be viewed as a practical goal,
radiation exposure can also be seen more generally as an
‘‘environmental exposure,’’ which now can be quantiﬁed. In
principle, it should be possible to extend the concept more
broadly to a variety of other relevant environmental agents,
such as toxins, carcinogens, and others that have a signiﬁcant
impact on human phenotypes. An ability to provide a
quantitative measure of the environmental contribution to
various phenotypes, along with measures of the genetic
contribution, could enhance the ability to more accurately
describe and understand these phenotypes.
Supporting Information
Figure S1. Distinct Gene Expression Proﬁles Are Activated as a
Function of Radiation Dose
(A) A Venn diagram of three mouse-metagene proﬁles is shown. The
diagram illustrates the number of genes within the 50-cGy, 200-cGy,
and 1,000-cGy mouse-metagene proﬁles and the intersection of genes
represented in common between the three proﬁles. Only ﬁve genes
were found to be in common between the three metagene proﬁles,
suggesting that distinct biological processes were activated as a
function of radiation dose.
(B) Quantitative real-time PCR analysis of representative genes within
the metagene proﬁles is shown. The fold changes in expression of
Ei24 (top) and Ptprcap (bottom) in the PB of irradiated mice are
shown relative to the nonirradiated control group. Error bars
indicate standard deviation. The levels of expression of these genes
correlated with that observed in the gene array analysis. A dose-
response to increasing radiation dose was observed with Ei24 but not
with Ptprcap.
Found at doi:10.1371/journal.pmed.0040106.sg001 (41 KB PPT).
Table S1. Genes that Distinguish Radiation Responses in Mice
Found at doi:10.1371/journal.pmed.0040106.st001 (342 KB DOC).
Table S2. Top Gene Predictor Functions Found within the Mouse
Prediction Model
Genes that were deﬁned in the metagenes were annotated in
GATHER (http://meddb01.duhs.duke.edu/gather/), which quantiﬁes
the evidence supporting the association between a gene group and
an annotation using a Bayes factor [41]. This assesses the hypothesis
that the distribution of annotations varies across gene groups against
the hypothesis that the distribution is identical. A positive Bayes
factor indicates that the evidence supports the association, while a
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Metagene of Radiation Responsenegative one indicates no association. Its magnitude corresponds to
the strength of the evidence for the association, where higher values
are stronger (ln[Bayes factor]). The ten most signiﬁcant ontology
annotations are shown in order of decreasing signiﬁcance. The most
highly represented biological processes for each radiation dose are
shown in the left column. The middle column shows the number of
genes within the metagene against the number of annotated genes
within the mouse genome. The far right column shows the Bayes
factor and those genes within the radiation signature that are found
within the biological process.
Found at doi:10.1371/journal.pmed.0040106.st002 (55 KB DOC).
Table S3. Patient Characteristics
Found at doi:10.1371/journal.pmed.0040106.st003 (26 KB DOC).
Table S4. Genes that Distinguish Radiation Response in Humans
Found at doi:10.1371/journal.pmed.0040106.st004 (45 KB DOC).
Table S5. Top Gene Predictor Functions Found within the Human
Prediction Model
Genes that were deﬁned in the human radiation metagenes were
annotated in GATHER (http://meddb01.duhs.duke.edu/gather/) [41]
and represented as described in Table S2.
Found at doi:10.1371/journal.pmed.0040106.st005 (45 KB DOC).
Accession Numbers
The Gene Expression Omnibus (GEO [http://www.ncbi.nlm.nih.gov/
geo]) accession number for the microarray data from this study is
GSE6874.
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Metagene of Radiation ResponseEditors’ Summary
Background. Everyone living on earth is constantly exposed to low
levels of ionizing radiation—energy in the form of waves or particles that
is powerful enough to strip electrons out of atoms and to break chemical
bonds in important biomolecules. These low levels of ionizing radiation
come from radioactive chemicals in the ground and cosmic rays, for
example, and are relatively harmless. Occasionally, though, individuals
are exposed to larger amounts of ionizing radiation, often as a result of
medical tests and treatments but sometimes through the accidental or
deliberate release of radioactive chemicals. These larger doses, which
permanently damage or kill cells, can cause radiation sickness, a
condition characterized by bone marrow failure, gut problems,
susceptibility to bacterial infections, and other symptoms that develop
days or months after exposure to ionizing radiation. Particularly large
doses can be lethal but even moderate doses can increase an individual’s
risk of developing cancer later in life.
Why Was This Study Done? Some of the effects of ionizing radiation
can be reduced if suitable treatment is started immediately after
exposure. Unfortunately, it takes several days to estimate the amount of
ionizing radiation to which an individual has been exposed. It would be
useful to measure personal exposures more quickly, especially in
emergency situations where ideally doctors would be able to distinguish
rapidly and accurately between the ‘‘worried well’’ and exposed
individuals. As cells respond to irradiation by altering the expression of
some genes, the researchers in this study investigated whether gene
expression profiling (a molecular biology technique that catalogues all
the genes expressed by a cell) can be used to define a set of gene
expression changes—called a metagene—that differentiates between
irradiated and non-irradiated cells.
What Did the Researchers Do and Find? The researchers exposed mice
to no ionizing radiation, a low dose that causes no medical problems, an
intermediate dose that damages blood cells, or a lethal dose. Six hours
later, they isolated blood cells from the mice, and catalogued which
genes each sample expressed. Using this information, the researchers
identified and validated metagenes that accurately distinguished
between blood samples from non-irradiated and irradiated animals
and between samples from animals exposed to different radiation doses.
The researchers then developed a metagene for human radiation
exposure using blood samples taken from patients before and after total
body irradiation given as part of their medical treatment. This metagene
correctly identified 18 of 20 pre-irradiation samples and 17 of 20 post-
irradiation samples. Finally, the researchers tested whether the radiation
metagenes developed in mice could distinguish between samples taken
from irradiated and non-irradiated people. Although the high-dose
mouse metagene correctly identified all of the samples from healthy
donors as being non-irradiated, it correctly identified only two-thirds of
the pre-irradiated samples from patients.
What Do These Findings Mean? These findings indicate that
metagenes can be generated that recognize different levels of radiation
exposure in mice and people. In the mouse study a metagene was
identified that correctly identified in all cases whether a sample came
from a non-irradiated mouse or an animal exposed to the lowest dose of
radiation. This result suggests that it might be possible to use a
metagene to identify exposed individuals among thousands of ‘‘worried
well’’ after a radiation emergency. First, however, the mouse and human
metagenes identified here need to be refined to improve their accuracy
and then validated in more people. The current high-dose mouse
metagene may be bad at identifying non-irradiated patients, for
example, because of gene expression changes that are a result of the
patients’ underlying disease or previous medical treatments. By studying
additional patients, it might be possible to improve the accuracy of the
metagene by taking these radiation-independent changes into account.
Finally and more generally, these findings suggest that the metagene
approach could be used to monitor people’s exposure to other
dangerous environmental agents.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040106.
  US Environmental Protection Agency offers information on
understanding radiation and factsheets on ionizing radiation
  MedlinePlus provides links to information on radiation exposure and
pages on radiation sickness
  US Centers for Disease Control and Prevention has information on
emergency preparedness and response to radiation emergencies
  Wikipedia has pages on ionizing radiation, radiation poisoning, and
expression profiling (note that Wikipedia is a free online encyclopedia
that anyone can edit)
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